热门资讯> 正文

Pacira聘请Molteni扩大EXPAREL在欧盟和英国的销售

2026-10-05 20:32

Pacira BioSciences(PCRX) 0

Pacira BioSciences (PCRX) signed an exclusive agreement with Molteni Farmaceutici to distribute and commercialize EXPAREL in the European Union and U.K.
Under the agreement, Pacira will receive an undisclosed upfront payment, a supply price, and royalties on future commercial sales in the licensed territories. Pacira will continue to manufacture EXPAREL, while Molteni will oversee regulatory, market access, and commercialization activities.
Molteni plans to launch EXPAREL sequentially in Italy, Germany, Austria, and Poland, with plans to seek approval in Switzerland; the first commercial sale is expected in 2027.

More on Pacira BioSciences

Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform
Pacira BioSciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Pacira outlines $735M-$760M 2026 revenue guidance while targeting 160M EXPAREL covered lives
Pacira BioSciences Non-GAAP EPS of $0.75 beats by $0.10, revenue of $192.4M beats by $1.4M

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。